Drugs / AAVB-039
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07161544 | Sep 2025 → Jul 2032 expected | Stargardt disease | AAVantgarde Bio Srl | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AAVB-039 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07161544 ↗ |